You are here

Article Text

Article menu
Download PDFPDF
Letters
Successful use of bortezomib in a patient with systemic lupus erythematosus and multiple myeloma
  1. Karen Fröhlich1,
  2. Julia U Holle1,
  3. Peer M Aries2,
  4. Wolfgang L Gross1,
  5. Frank Moosig1
  1. 1University of Lübeck, Department of Rheumatology and Klinikum Bad Bramstedt, Bad Bramstedt, Germany
  2. 2Rheumatologie im Struenseehaus, Hamburg, Germany
  1. Correspondence to Frank Moosig, University of Lübeck, Department of Rheumatology and Klinikum Bad Bramstedt, Oskar-Alexander-Straße 26, 24576 Bad Bramstedt, Germany; moosig{at}klinikumbb.de

https://doi.org/10.1136/ard.2010.133256

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Background

    Bortezomib belongs to the family of proteasome inhibitors and is a well established first line drug in multiple myeloma (MM).1 In mouse models of lupus nephritis, bortezomib ameliorated glomerulonephritis, prolonged survival and reduced autoantibody production.2

    Case report

    We report the case of a 63-year-old woman who presented with systemic lupus erythematosus (SLE) fulfilling the American College of Rheumatology (ACR) criteria and requiring treatment for autoimmune thrombocytopoenia, Coombs positive autoimmune haemolytic anaemia, polyarthritis and hair loss. Anti-nuclear antibody (ANA), extractable nuclear antigen (ENA) (U1 riboucleoprotein (U1RNP)) and anti-double-stranded (ds)DNA antibody tests were positive, and serum complement C3 and C4 levels were decreased (European Consensus …

    View Full Text

    Footnotes

    • Competing interests None.